ALPHA-7 NICOTINIC RECEPTOR AGONISTS AND STATINS IN COMBINATION

Details for Australian Patent Application No. 2003256203 (hide)

Owner ASTRAZENECA AB

Inventors KEITH, Richard

Pub. Number AU-A-2003256203

PCT Number PCT/SE03/01352

PCT Pub. Number WO2004/019947

Priority 0202598-9 02.09.02 SE

Filing date 1 September 2003

Wipo publication date 19 March 2004

International Classifications

A61K 031/505 - Pyrimidines

A61K 031/439 - the ring forming part of a bridged ring system, e.g. quinuclidine

A61K 031/40 - having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

A61K 031/351 - not condensed with another ring

A61K 031/22

A61K 031/404

A61K 031/4418 - having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine

A61K 031/366 - having six-membered rings, e.g. delta-lactones

A61P 025/28 Drugs for disorders of the nervous system

Event Publications

6 November 2003 Complete Application Filed

  Priority application(s): 0202598-9 02.09.02 SE

6 May 2004 Application Open to Public Inspection

  Published as AU-A-2003256203

19 May 2005 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(f)/See Reg. 8.3(3). Examination has not yet been requested or directed for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003256204-A PULSED LASER AND A METHOD, COMPRISING A DIFFUSING ELEMENT TO EQUALIZE THE DIVERGENCE OF THE LASER RADIATION

2003256202-TARGETS FOR TYPE I AND TYPE II DIABETES